In a randomized, double-blind Phase 2 study of 77 patients with multiple system atrophy (MSA), ATH434 delivered a clinically...

ANAVEX3-71 met its primary endpoint in a placebo-controlled Phase 2 study in adults with schizophrenia on stable antipsychotic therapy,...

VQ-101 delivered more than 70% activation of lysosomal glucocerebrosidase in GBA-Parkinson’s patients after 28 days of once-daily dosing, exceeding...

ALX Oncology will present updated Phase 2 data from ASPEN-06, indicating that tumor CD47 overexpression may predict response to...

BriaCell will debut preclinical data for Bria-OTS+, an off-the-shelf cancer vaccine platform that aims to combine trained innate immunity...

No new clinical efficacy endpoints were disclosed. Vielight introduced a meditation-specific protocol within its Neuro Pro photobiomodulation device and...

CAMP4 Therapeutics has begun GLP toxicology studies for CMP-SYNGAP-01, an intrathecally delivered antisense oligonucleotide designed to upregulate SYNGAP1 expression...

After completing the initial 30 mCi cohort with acceptable safety, pharmacokinetics, and biodistribution, the Phase 1 HEAT study of...

Kura Oncology and Kyowa Kirin have dosed the first patient in a new cohort of the Phase 1b KOMET-007...

A 20-patient, single-site U.S. pilot has begun enrolling at Johns Hopkins under an FDA IDE to evaluate the safety...